Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
A top Marine shares his secrets to keeping fit at 50 - 2Cyclone causes blackout, flight chaos in Brazil's Sao Paulo
- 3This Week In Space podcast: Episode 204 — A New NASA
- 4The German series proving subtitles can be sexy — and wildly addictive
- 575% of Arab Israelis support Arab party joining government coalition post-war, survey reveals
- Israeli archaeologists launch project to trace origins of ancient pottery
- What do teens and tweens want for the holidays? E-bikes, gift cards and lip tints.
- Antimatter took to the road for the very first time. Here’s why it matters
- Putin critic gets six years in penal colony, vows hunger strike
- Consume Fat Quick: 10 Demonstrated Activities for Ideal Outcomes
- Journey Travel Objections for Your Next Experience
- Space debris: will it take a catastrophe for nations to take the issue seriously?
- Make your choice for the sweet that transports you to its nation of beginning!
- Best Amusement Park in Europe: Where Do You Very much want to Visit?
